Search - tctmd.com

Displaying 221 - 240 of 1061

Sort: Relevancy | Date

News Daily News

Aborted TAVR Procedures Are Waning in the US

Shelley Wood

August 28, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Michael O'Riordan

July 17, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

News Daily News

TAVR Growing in the US, but Vast Majority of Patients Not Receiving Any Form of Valve Replacement

Michael O'Riordan

June 12, 2019

News Daily News

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Yael L. Maxwell

June 11, 2019

News Conference News EuroPCR 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

Caitlin E. Cox

June 07, 2019

News Conference News EuroPCR 2019

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Michael O'Riordan

May 29, 2019

CHOICE: Better Hemodynamics, Less Structural Deterioration with CoreValve

News Conference News EuroPCR 2019

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Michael O'Riordan

May 24, 2019

News Conference News EuroPCR 2019

TAVR Durability ‘Snapshot’ Offers Some Reassurances 8 to 10 Years Out

Caitlin E. Cox

May 24, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Conference News EuroPCR 2019

Valve Leaflet Scoring Device for Aortic Stenosis Clears Feasibility Hurdle

Michael O'Riordan

May 23, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Industry News

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

April 23, 2019

News Daily News

Volume Still an Important Surrogate for TAVR Quality, New Data Suggest

Todd Neale

April 03, 2019

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

Todd Neale

March 25, 2019

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

Advertisement

Aborted TAVR Procedures Are Waning in the US

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

TAVR Growing in the US, but Vast Majority of Patients Not Receiving Any Form of Valve Replacement

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

TAVR Durability ‘Snapshot’ Offers Some Reassurances 8 to 10 Years Out

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Valve Leaflet Scoring Device for Aortic Stenosis Clears Feasibility Hurdle

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

Volume Still an Important Surrogate for TAVR Quality, New Data Suggest

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content